NovoCure Ltd. (NASDAQ: NVCR), a global oncology company, saw its stock plummet 5.3% in the intraday trading session on Friday, following the release of its full-year 2024 earnings results.
The company reported revenue of $605.2 million for the fiscal year 2024, up 19% year-over-year and in line with analyst estimates. However, NovoCure's earnings per share (EPS) fell short of expectations, missing by 20% at a loss of $1.56 per share.
The EPS miss appears to have weighed heavily on investor sentiment, as the company's shares had already experienced an 11% decline over the past week leading up to the earnings release. While NovoCure's revenue growth remained solid, the wider-than-expected net loss suggests potential challenges in managing costs or meeting profitability targets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.